AAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG today announced that the FDA has designated the company’s CoFI (Controlled Flow Infusion) System as a “Breakthrough Device” with a broad indication-for-use statement: “The CoFI System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a platform for controlled infusion of therapeutic agents into the microcirculation with or without vessel occlusion.”